ODR001 (in vitro derived platelets)
|Finished product||Platelets in suspension, generated from in vitro derived megakaryocytes through a microfluidic system|
|Primary indication||Treatment of thrombocytopenia in patients at risk of bleeding or with bleeding events|
|Development status||Pre-clinical stage|
Clinical development path will be discussed with Health Authorities, based on existing guidelines.
ODR001 efficacy will be assessed in clinical trials planned to start in 2017.